Skip to main content
. 2010 Jun 18;116(12):2033–2039. doi: 10.1182/blood-2010-03-273706

Figure 1.

Figure 1

Association between KIR3DS1 genotype and PFS. (A) PFS for GR patients who were KIR3DS1+ was significantly shorter than for GR patients who were KIR3DS1− (P = .003). The median PFS for poor-risk patients was not significantly different from GR, KIR3DS1+ patients (P = .061). (B) Among patients with GR disease at ASCT, those with KIR3DS1+/KIR3DL1+/HLA-Bw4− have significantly reduced PFS than patients with KIR3DS1+/KIR3DL1+/HLA-Bw4+ and patients with KIR3DS1− irrespective of HLA-Bw4 (P = .002).